Overview


According to FutureWise analysis, the market for Drug Formulation is expected to grow with a CAGR of 6.05% over the forecast period 2023-2031, and reach a market value of US$ 2.78 trillion by 2031.

Drug formulation is the process of designing and developing a drug product that contains an active pharmaceutical ingredient (API) along with other ingredients (known as excipients) to achieve a specific dosage form. The goal of drug formulation is to create a stable, safe, and effective product that can be administered to patients in a convenient and reliable manner. A drug formulation can take various forms, including, Oral formulations are drugs designed to be taken by mouth, such as tablets, capsules, syrups, and suspensions. Topical formulations are applied to the skin or mucous membranes, including creams, ointments, gels, patches, and foams. Additionally, injectable formulations are solutions or suspensions that are administered via injection, either intravenously (into a vein), intramuscularly (into a muscle), subcutaneously (under the skin), or intradermally (into the skin). Inhalable formulations are designed to be inhaled into the lungs and can include aerosols, inhalers, and nebulizers.

Drug formulations tailored to specific therapy areas play a vital role in managing different health conditions. In Cardiovascular Diseases (CVDs), medications like Beta Blockers and ACE Inhibitors are commonly administered in oral tablet or capsule forms, with extended-release options for some. Statins, crucial for cholesterol management, are typically available in tablet form, and Anticoagulants may be administered orally or through injectable solutions. Meanwhile, for alleviating Pain, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) such as Ibuprofen are dispensed in tablets, capsules, or even topical applications in the form of creams or gels. Diabetes management often involves Insulin, which is available in injectable solutions through vials or pre-filled pens and long-acting formulations. Oral Hypoglycemic Agents like Metformin are distributed in tablet form, including extended-release varieties.

FutureWise Market Research has published a report that provides an insightful analysis drug formulation market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts drug formulation market estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • 3M Company
  • Bayer AG
  • Teva Pharmaceuticals Industries Ltd.
  • Amgen, Inc.
  • Sanofi SA
  • GlaxoSmithKline plc
  • Boston

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Drug Formulation Market:

  • In June 2022, Bristol Myers Squibb and Turning Point Therapeutics formalized a conclusive merger agreement. As Turning Point Therapeutics is a precision oncology company still in clinical development, this acquisition will significantly bolster BMS's selection of oncology medications. This strategic move not only expands BMS's portfolio but also increases its capacity to develop innovative drug formulations customized to specific cancer subtypes, potentially revolutionizing the field of oncology treatment.

The increasing innovations in drug delivery systems, like the development of nanoparticles, liposomes, and implantable technologies, may increase the demand for the drug formulation market. These advancements revolutionize how pharmaceuticals are administered, allowing targeted and controlled release of medications into the body. Nanoparticles, for instance, allow for accurate delivery to specific tissues or cells, enhancing therapeutic efficacy while minimizing side effects. Liposomes serve as versatile carriers, encapsulating drugs for improved stability and controlled release. Implants deliver sustained and localized delivery, which is especially beneficial for long-term treatments. Moreover, the rising incidences of chronic diseases, such as diabetes, cardiovascular disorders, and cancer, constitute a major driver in the drug formulation market. This surge in chronic illnesses requires more effective and targeted therapeutic solutions. Advanced drug formulations designed to optimize treatment outcomes while minimizing undesirable side effects are in high demand. For instance, formulations that offer sustained release or are tailored to specific patient profiles hold the promise of better disease management. These innovations not only address critical medical needs but also signify a complete shift towards more personalized and efficient healthcare approaches, thus boosting the evolution of the drug formulations market. However, the formidable constraints facing the drug formulation market include the substantial cost and temporal investments required for the research, development, and rigorous testing of advanced drug formulations. This demanding process may pose a significant hurdle, particularly for smaller pharmaceutical companies with limited resources. Moreover, many blockbuster drugs have gone off-patent, leading to increased competition from generic drug manufacturers, which may further reduce the profitability of innovative drug formulations. Therefore, hindering the growth of the market.

By Formulation

  • Tablets
  • Capsules
  • Injectable
  • Sprays
  • Suspensions
  • Powders
  • Other Formulations

By Routes of Administration

  • Oral
  • Topical
  • Parenteral
  • Inhalations
  • Other Routes of Administration

By Therapy Area

  • Cardiovascular Diseases (CVDs)
  • Pain
  • Diabetes
  • Cancer
  • Respiratory Diseases
  • Other Diseases

By End-User

  • Retail
  • Non-retail

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Due to advanced technologies, rising expenditures, ongoing global immunization campaigns, the need for critical and elective medical treatments, strategic pharmaceutical alliances, well-established healthcare infrastructure, an increase in the prevalence of chronic conditions, and increasing investment flows in the region are expected to drive the market expansion. Furthermore, the majority of clinical trials and drug efficacy studies conducted, ongoing research and development, mergers and acquisitions strategies, and product development further propelled the growth of the market. Therefore, the above-mentioned factors are likely to fuel the target market over the projection period.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Drug Formulation Market By Formulation, By Route of Administration, By Therapy Area, By End User, and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2 Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Drug Formulation Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Drug Formulation Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Drug Formulation Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Drug Formulation Market, By Formulation Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Tablets    
        2. Capsules
        3. Injectable
        4. Sprays
        5. Suspensions
        6. Powders
        7. Other Formulations

  • 8.  Drug Formulation Market, By Routes of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Topical
        3. Parenteral
        4. Inhalations
        5. Other Routes of Administration

  • 9.  Drug Formulation Market, By Therapy Area Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Cardiovascular Diseases (CVDs)
        2. Pain
        3. Diabetes
        4. Cancer
        5. Respiratory Diseases
        6. Other Diseases

  • 10.  Drug Formulation Market, By End-User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Retail    
        2. Non-retail

  • 11.  North America Drug Formulation Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.  Latin America Drug Formulation Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.  Europe Drug Formulation Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.  Asia Pacific Drug Formulation Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031  

  • 15.  Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 17.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Bristol-Myers Squibb
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Eli Lilly and Company
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Gilead Sciences, Inc.
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Merck & Co., Inc.
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Novartis AG
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. Pfizer Inc.
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. AbbVie Inc.
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. Boehringer Ingelheim International GmbH
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. F. Hoffmann-La Roche AG
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. Johnson & Johnson
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview
        11. 3M Company
           11.1. Company Overview
           11.2. Product Portfolio
           11.3. SWOT Analysis
           11.4. Financial Overview
           11.5. Strategic Overview
        12. Bayer AG
           12.1. Company Overview
           12.2. Product Portfolio
           12.3. SWOT Analysis
           12.4. Financial Overview
           12.5. Strategic Overview
        13. Teva Pharmaceuticals Industries Ltd.
           13.1. Company Overview
           13.2. Product Portfolio
           13.3. SWOT Analysis
           13.4. Financial Overview
           13.5. Strategic Overview
        14. Amgen, Inc.
           14.1. Company Overview
           14.2. Product Portfolio
           14.3. SWOT Analysis
           14.4. Financial Overview
           14.5. Strategic Overview
        15. Sanofi SA
           15.1. Company Overview
           15.2. Product Portfolio
           15.3. SWOT Analysis
           15.4. Financial Overview
           15.5. Strategic Overview
        16. GlaxoSmithKline plc
           16.1. Company Overview
           16.2. Product Portfolio
           16.3. SWOT Analysis
           16.4. Financial Overview
           16.5. Strategic Overview
        17. Boston
           17.1. Company Overview
           17.2. Product Portfolio
           17.3. SWOT Analysis
           17.4. Financial Overview
           17.5. Strategic Overview

  • 18.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients